Financial Health Snapshot
What does Charles River Laboratories International, Inc. (CRL)’s latest financial snapshot show?
Mixed. The strongest factor is the $37500M–$40000M free cash flow outlook, while the main concern is organic revenue decline and margin compression.
The latest verified period is Q1 2026. This verdict combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency, so it reflects both reported revenue strength and the weaker underlying demand trend. For mission and strategy context, see Mission Statement, Vision, & Core Values (2026) of Charles River Laboratories International, Inc. (CRL).
Free cash flow deserves deeper analysis first because it shows whether Charles River Laboratories International, Inc. can fund operations, debt service, and investment while organic revenue decline and margin pressure weigh on current performance.
Revenue Quality
Are Charles River Laboratories International, Inc. (CRL) revenue and earnings durable?
Mixed. CRL’s latest reported growth looks better on paper than on a comparable organic basis, but the clearest divergence is that Q1 2026 revenue growth of 120% came alongside organic revenue decline of 150%, while GAAP earnings stayed negative.
Investors need to separate growth in reported revenue from growth in durable earnings because acquisitions, divestitures, FX, and mix can distort the headline number. Comparing revenue with operating income, net income, and EPS across compatible annual periods shows whether CRL is actually turning sales into repeatable profit.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $99600M in Q1 2026; reported growth of 120% | $99583M in the related prior-quarter evidence | Reported growth is not cleanly organic; organic revenue declined 150% | The growth source looks less repeatable until stripped of acquisition, divestiture, FX, and mix effects |
| Operating Income | $11990M in Q1 2026 | Previous comparable value not supplied | Direction is positive, but the operating leverage comparison is incomplete | Operating strength is harder to confirm without a like-for-like prior-period base |
| Net Income | -$1484M in Q1 2026 | Previous comparable value not supplied | GAAP loss while non-GAAP EPS was $206 | Final earnings do not fully confirm the revenue result because adjustments matter |
| Diluted EPS | -$030 in Q1 2026 | Previous comparable diluted EPS not supplied | GAAP EPS was negative despite positive non-GAAP EPS | Shareholders did not see the same earnings strength that adjusted results suggest |
How durable is Charles River Laboratories International, Inc. (CRL)’s revenue?
Durability is supported by booking visibility, but the largest limitation is that the revenue base is being reshaped by divestitures and non-organic effects. Q4 2025 net bookings of $64000M and biotech client net book-to-bill above 10x for two straight quarters are the strongest signals.
- Demand Quality: Recurring research and biotech demand looks visible from bookings, but revenue durability is still affected by divestitures and mix changes.
- Pricing and Volume: The split is unavailable here; reported growth and organic decline point to non-volume effects and comparability noise.
- Diversification: CRL has scale across DSA and RMS, but divestitures of CDMO, Cell Solutions, and European Discovery sites reduce the future revenue base.
That makes profitability and cash conversion the next test.
Profitability and Cash
Is Charles River Laboratories International, Inc. turning revenue into cash efficiently?
Not yet clearly. Charles River Laboratories International, Inc. posted weaker margins and a negative net margin in Q1 2026, while the supplied cash data shows weaker operating and free cash conversion. The $37.5 million–$40.0 million full-year 2026 free cash flow outlook still needs margin improvement to prove earnings quality.
Gross margin shows how much of each sales dollar is left after direct costs, operating margin shows how much remains after overhead, and net margin shows final profit after interest and taxes. For Charles River Laboratories International, Inc., the latest quarter’s net loss and weaker cash conversion matter more than revenue alone, especially with the linked business overview in Charles River Laboratories International, Inc. (CRL): History, Ownership, Mission, How It Works & Makes Money.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | 28.04% for Q1 2026 | Unavailable | Higher study-related direct costs ضغط gross profitability. | Product and service economics are under pressure, so revenue quality is not yet improving cleanly. |
| Operating Margin | 16.30% non-GAAP for Q1 2026 | 19.10% non-GAAP for Q1 2025 | Higher study-related direct costs and CEO transition-related stock compensation expenses outweighed some SG&A improvement. | Scale is not fully improving efficiency yet, even with cost actions underway. |
| Net Margin | -1.49% for Q1 2026 | Unavailable | Net loss reflects operating pressure and other below-operating items. | Final profitability does not yet confirm strong earnings quality. |
| Operating Cash Flow | Unavailable for 2026-03-28 | Unavailable | Supplied growth data shows -7215%, signaling weaker cash conversion. | Reported earnings are not yet confirmed by operating cash flow data in the supplied record. |
| Free Cash Flow | $37.5 million–$40.0 million outlook for full-year 2026 | Unavailable | Guidance reflects the burden of capital spending and operating friction. | There is still room for reinvestment and financing, but cash generation must improve. |
What most affects Charles River Laboratories International, Inc. cash conversion?
Higher study-related direct costs and transition-related stock compensation are the biggest drags, while the company’s cost-savings plan may help later. The supplied cash data still points to weaker conversion, so the improvement looks incomplete rather than structural.
- Main Driver: Study-related direct costs and CEO transition stock compensation appear temporary, but they are still pressuring near-term cash conversion.
- Evidence Gap: The supplied data does not give actual operating cash flow or free cash flow for Q1 2026.
- Metric to Monitor: Track second-half operating margin and full-year free cash flow against the $37.5 million–$40.0 million outlook.
Liquidity Check
Does Charles River Laboratories International, Inc. have enough financial capacity to support its obligations and investment needs?
Mixed. Charles River Laboratories International, Inc. has solid liquidity and a large asset base, but debt, buybacks, and acquisition funding are the main pressure points. The key protection is $19183M of cash and cash equivalents; the main concern is that capital demands can crowd each other out.
Cash alone is not enough here. The balance sheet has to cover working capital, asset quality, debt service, solvency, liquidity, and refinancing together, especially because Charles River Laboratories International, Inc. is balancing operations, reinvestment, acquisitions, divestiture transitions, and repurchases at the same time.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | $19183M cash and cash equivalents; $149B total current assets; $70025M net receivables; $35972M inventory. | Mixed | Near-term obligations look manageable, but cash must also support operations and growth spending. |
| Total and Net Debt | $306B total debt and $19183M cash and cash equivalents, both as of 2026-03-28. | Mixed | Leverage limits flexibility, so debt needs to be watched alongside acquisition and repurchase plans. |
| Debt Service and Refinancing | $2674M interest expense and -$2571M net interest income for 2026-03-28; $20000M shares repurchased in Q1 2026 under a $100B board authorization. | Mixed | Capacity looks workable, but cash generation has to cover interest plus capital returns and future refinancing needs. |
| Asset Quality | $183B property, plant and equipment, net; $304B goodwill; $24899M intangible assets; $329B goodwill and intangible assets. | Mixed | The asset base is large, but heavy goodwill and intangibles raise impairment risk if performance weakens. |
| Liabilities and Equity | Total liabilities and shareholders' equity were not separately provided in the supplied data; total assets were $773B. | Mixed | Investors can see scale, but full obligation coverage cannot be tested without the missing equity and liability detail. |
Which balance-sheet risk matters most for Charles River Laboratories International, Inc.?
Funding pressure is the biggest risk. Debt, acquisitions, and repurchases all compete for the same cash pool, so liquidity discipline matters more than headline asset size.
- Current Exposure: $19183M cash, but also $306B total debt and $20000M repurchased in Q1 2026.
- Protection: $149B total current assets plus a large asset base provide operating and financing flexibility.
- Warning Signal: Watch whether free cash flow reaches the $37500M–$40000M outlook, because that would better support capital needs.
Capital Efficiency
Is Charles River Laboratories International, Inc. (CRL) using capital efficiently?
CRL looks Mixed. The recent mix of 834% asset growth and -644% book value per share growth raises a capital efficiency question, but internal cash may still support part of reinvestment if divestiture proceeds and operating cash flow hold up.
Return quality at CRL should be judged with leverage, asset intensity, capital expenditure, working capital, and outside funding needs, not just growth alone. The Exploring Charles River Laboratories International, Inc. (CRL) Investor Profile: Who's Buying and Why? view matters because the same capital base is being used for modernization, automation, and portfolio reshaping.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable; no supplied ROIC for 2026-03-28. | Asset growth of 834% and negative book value per share growth of -644% suggest investors should test whether operating margins and capital turns support the expansion. | Invested capital may be building future value, but the current evidence does not confirm strong operating value creation. |
| ROE and ROA | ROE and ROA are unavailable; weighted average shares growth was -054% and diluted shares growth was -054%. | Lower share count can support ROE, but the sharp asset buildup can दबute ROA if earnings do not rise at the same pace. | Shareholder return quality is unclear, and asset efficiency looks like the key watch item rather than leverage alone. |
| Maintenance and Growth Investment | Pathway to Purpose focuses on modernizing operations, automating workflows, specializing in core DSA services, AI-powered digital pathology workflows, and an Alternative Methods Advancement Program that plans to invest $30000M over five years. | These are mostly growth and capability investments, not just maintenance spending. | CRL appears to need substantial capital to sustain service upgrades, speed, and specialization. |
| Internal Funding Capacity | CRL completed $14500M of cash divestitures through the CDMO and Cell Solutions sale to GI Partners and European Discovery site sales to IQVIA, and it also executed $20000M of buybacks in Q1 2026. | Cash generation, divestiture proceeds, debt, acquisitions, and technology spending must all be weighed together. | Investment looks partly internally funded, but capital returns and reinvestment needs could still require outside flexibility. |
Are Charles River Laboratories International, Inc. (CRL) returns on capital sustainable?
Potentially, yes. The strongest durability source is specialization in core DSA services with automation and AI-powered pathology, but returns could weaken if the $30000M investment plan and $20000M buybacks strain cash or if asset growth outpaces earnings.
- Operating Source: DSA focus, automated workflows, and AI pathology should improve efficiency and shorten timelines by one week.
- Funding Requirement: The biggest verified need is the $30000M five-year Alternative Methods Advancement Program.
- Durability Test: Returns weaken if asset growth stays high while book value per share remains negative and cash flow cannot cover reinvestment plus buybacks.
Financial Resilience
How resilient is Charles River Laboratories International, Inc. to weaker demand, margin pressure, and rising cash needs?
Resilience is Mixed. The main buffer is strong biotech client demand momentum, shown by Q4 2025 net bookings of $640.00M and a biotech client net book-to-bill above 1.0x for two straight quarters. The most important verified warning sign is the projected 0% to 1.5% organic revenue decline for full-year 2026.
Charles River Laboratories International, Inc. has enough business scale and client backlog to support liquidity and core investment, but weaker demand, margin pressure, and acquisition-related cash use could still tighten flexibility. The company is also facing a 4.00% to 5.50% reported revenue decline outlook because of a stronger US dollar, which adds another layer of pressure. For background on the business model, see Charles River Laboratories International, Inc. (CRL): History, Ownership, Mission, How It Works & Makes Money.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Projected organic revenue decline of 0% to 1.5% for full-year 2026 and Q1 2026 organic revenue decline of 1.5% could reduce operating leverage, earnings, cash flow, and debt capacity. Q1 2026 non-GAAP operating margin of 16.30% fell 280 basis points year over year. | Q4 2025 net bookings of $640.00M and biotech client net book-to-bill above 1.0x for two consecutive quarters suggest demand support. The company also targets $10.00M of incremental cost savings in 2026 and 120 to 150 basis points of operating margin improvement. | Watch for continued organic revenue decline, weaker bookings, or further margin compression. |
| Working-Capital or Investment Pressure | Higher study-related direct costs, CEO transition-related stock compensation expenses, and acquisition spending can absorb cash and limit flexibility for R&D, capex, and other investment needs. | Charles River Laboratories International, Inc. reports $19.183M in cash and cash equivalents and relies on internal sourcing for most NHP requirements through Noveprim and KF (Cambodia) assets. | Monitor free cash flow versus cash uses, plus any rise in asset growth or investment intensity. |
| Interest or Refinancing Pressure | $3.06B of total debt increases sensitivity to interest expense and refinancing conditions if cash flow weakens. | Liquidity is supported by cash on hand and operating cash generation, while the KF (Cambodia) Ltd acquisition agreement for $51.000M is relatively small versus total debt. | Look for rising debt, weaker interest coverage, or tightening free cash flow after funding needs. |
Which financial warning signs should investors monitor at Charles River Laboratories International, Inc.?
The strongest signals are organic revenue trend, operating margin, and free cash flow versus cash uses. Confirmed deterioration would be sustained revenue decline or margin compression; future risk is funding pressure if debt, acquisition spending, or working capital absorbs more cash.
Organic Revenue Decline
The clearest warning is the 0% to 1.5% full-year 2026 organic revenue decline outlook and Q1 2026 organic revenue decline of 1.5%. Demand is still supported by bookings, but a longer downturn would weaken operating leverage and cash generation.
Margin Compression From Cost Pressure
Q1 2026 non-GAAP operating margin fell to 16.30%, down 280 basis points year over year. Higher study-related direct costs and CEO transition-related stock compensation expenses matter because they can limit cash flow unless the $10.00M savings plan shows up in results.
Debt and Cash-Use Strain
$3.06B of debt against $19.183M of cash and cash equivalents is not a crisis by itself, but it raises sensitivity to weaker cash flow. Investors should track free cash flow, because acquisition spending and supply-chain intensity can reduce flexibility.
Bottom-Line Health
What does Charles River Laboratories International, Inc.’s financial health mean for investors?
Overall, the verdict is Mixed. The strongest factor is the $37500M–$40000M free cash flow outlook, while the weakest is organic demand and margin pressure. The most important condition is whether internal funding can keep supporting recovery, buybacks, and acquisitions without stretching leverage.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Mixed | Q1 2026 revenue was $99600M with 120% reported growth, but 150% organic revenue decline and -$1484M GAAP net income weaken quality. |
| Profitability and Cash | Mixed | Non-GAAP operating margin was 1630%, and free cash flow guidance is $37500M–$40000M, but margin fell 280 basis points year over year. |
| Balance Sheet and Liquidity | Mixed | Cash and cash equivalents were $19183M and total current assets were $149B, but add total debt was $306B, so leverage still needs monitoring. |
| Capital Efficiency | Mixed | Buybacks, divestitures, automation, and AMAP can improve focus, but ROIC, ROE, and ROA are not available and book value per share growth was -644%. |
| Financial Resilience | Mixed | Bookings, vertical NHP supply integration, and cost savings help, but organic decline, FX headwinds, study-related direct costs, and acquisition funding demands remain real pressure points. |
- What Supports the Thesis: Internal funding capacity is strong enough to support operations, buybacks, and strategic actions if cash generation holds.
- What Challenges the Thesis: Organic demand weakness and margin pressure make it hard to trust the earnings recovery.
- What to Monitor: Organic revenue decline, non-GAAP operating margin, free cash flow.
For readers building a case study, Exploring Charles River Laboratories International, Inc. (CRL) Investor Profile: Who's Buying and Why? can help connect this balance-sheet view to scenarios, forecasts, and valuation inputs.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
Why can GAAP losses coexist with non-GAAP EPS?
CRL reported Q1 2026 Net Income of -$1484M and non-GAAP EPS: $206 The gap signals that investors must inspect adjustments before judging earnings quality A non-GAAP profit measure can support operating analysis, but GAAP losses still matter for resilience
Can CRL fund buybacks and growth internally?
CRL’s Free Cash Flow Outlook is $37500M–$40000M for full-year 2026, while Q1 2026 repurchases were $20000M Internal funding looks possible if free cash flow guidance is met, but debt, acquisitions, and technology investments compete for the same cash
What supports CRL’s free cash flow outlook?
The outlook is supported by planned efficiency actions, including $10000M incremental cost savings targeted for 2026 and an annualized goal of $30000M from multi-year actions Investors should verify support through operating margin, working capital, and actual free cash flow delivery
How exposed is CRL to currency pressure?
Currency is a current financial headwind CRL reduced its revenue outlook by 50 basis points to 400%–550% decline on a reported basis due to US dollar strengthening The key issue is whether FX pressure offsets organic stabilization and margin recovery
Which metric best signals margin recovery?
Non-GAAP operating margin is the cleanest headline metric to monitor Q1 2026 Operating Margin was 1630% and down 280 basis points year-over-year Investors should compare that with the targeted full-year improvement of 120–150 basis points